These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 20608988)

  • 1. Gender and the renin-angiotensin-aldosterone system.
    Komukai K; Mochizuki S; Yoshimura M
    Fundam Clin Pharmacol; 2010 Dec; 24(6):687-98. PubMed ID: 20608988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Possibilities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone system].
    Maksimov ML
    Ter Arkh; 2010; 82(6):77-80, inside back cover. PubMed ID: 20731118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 5. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
    Gensini GF; Lippi D; Conti AA
    Recenti Prog Med; 2002 Oct; 93(10):544-53. PubMed ID: 12405014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To live alone and to be depressed, an alarming combination for the renin-angiotensin-aldosterone-system (RAAS).
    Häfner S; Baumert J; Emeny RT; Lacruz ME; Bidlingmaier M; Reincke M; Kuenzel H; Holle R; Rupprecht R; Ladwig KH;
    Psychoneuroendocrinology; 2012 Feb; 37(2):230-7. PubMed ID: 21742440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in the cardiovascular effects of sex hormones.
    Vitale C; Fini M; Speziale G; Chierchia S
    Fundam Clin Pharmacol; 2010 Dec; 24(6):675-85. PubMed ID: 20199585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease.
    Re RN
    Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):42-7. PubMed ID: 16265259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex and the renin angiotensin system: implications for gender differences in the progression of kidney disease.
    Sandberg K; Ji H
    Adv Ren Replace Ther; 2003 Jan; 10(1):15-23. PubMed ID: 12616459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
    Turgut F; Balogun RA; Abdel-Rahman EM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension in women: the role of progesterone and aldosterone.
    Boschitsch E; Mayerhofer S; Magometschnigg D
    Climacteric; 2010 Aug; 13(4):307-13. PubMed ID: 20443718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.